Medpace Holdings Inc
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2023, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as described in the table below:
- 75 -
| Action | Date | Trading Arrangement | Total Shares to be Purchased or Sold | Duration/Expiration Date | ||
| Rule 10b5-1* | Non-Rule 10b5-1** | |||||
|---|---|---|---|---|---|---|
| Medpace Investors, LLC [1] | Adopt | November 14, 2023 [2] | X | Up to 25,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 15, 2023 [3] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 17, 2023 [4] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 20, 2023 [5] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 21, 2023 [6] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 27, 2023 [7] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Medpace Investors, LLC [1] | Adopt | November 29, 2023 [8] | X | Up to 50,000 shares to be sold | Good until cancelled | |
| Susan E. Burwig, Executive Vice President, Operations | Adopt | December 14, 2023 [9] | X | Up to 12,400 shares to be sold | The earlier of until cancelled or 180 days from the placement of the limit order | |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
[1]August J. Troendle, Chief Executive Officer and Chairman of the Board of the Company, is the sole manager and controlling unit holder of Medpace Investors, LLC (“MPI”) and has sole voting and investment control with respect to the securities held by MPI. Mr. Troendle may be deemed to indirectly beneficially own the securities of the Company held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
[2] On November 14, 2023, MPI placed a limit order to sell up to 25,000 shares that were previously acquired through open market purchases.
[3] On November 15, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
[4] On November 17, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
[5] On November 20, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
[6] On November 21, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
[7] On November 27, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
[8] On November 29, 2023, MPI placed a limit order to sell up to 50,000 shares that were previously acquired through open market purchases.
- 76 -
[9] On December 14, 2023, Ms. Burwig placed a limit order to sell up to 12,400 shares that were previously acquired through an exercise of stock options.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.